China Pharma Market Access (CPMA)

Since the establishment of the China National Medical Insurance Bureau in 2018, the goal has been to strengthen public health and medical service levels, achieve maximum utilisation of the national medical insurance fund, and to enhance the strategic purchasing capability of medical insurance funds. Significant tools in achieving this are the National Reimbursement Drug List (NRDL) and drug Volume Based Procurement (VBP), which have opened a new chapter in China’s medical reform. Meanwhile, the new drug registration process is improved, simplified, and accelerated.

Deallus’ Chinese pharmaceutical market access model revolves around the following five aspects: company’s vision and objectives, drug discovery innovation, registration for approval, National Reimbursement Drug List (NRDL), Volume-based procurement (VBP) and pricing, Hospital Drug Listing (HDL) and physician perception building.

Download to read more.

China Market Access Whitepaper - August 2023
DOWNLOAD PAPER

You may also be interested in…

  • National Healthcare Security Administration (NHSA) protocols

National Healthcare Security Administration (NHSA) protocols

On 4 July 2023, the National Healthcare Security Administration (NHSA) published the drafted 'Protocol for Renewal of NRDL Listed Drugs’ and ‘Negotiation Rules for Non-Exclusive Drug’. The two protocols aim to streamline the negotiation process for NRDL listed drugs and those with generic versions and are eligible for NRDL listing.

  • China Pharma Market Access

China Pharma Market Access (CPMA)

Since the establishment of the China National Medical Insurance Bureau in 2018, the goal has been to strengthen public health and medical service levels, achieve maximum utilisation of the national medical insurance fund, and to enhance the strategic purchasing capability of medical insurance funds. Significant tools in achieving this are the National Reimbursement Drug List (NRDL) and drug Volume Based Procurement (VBP), which have opened a new chapter in China’s medical reform. Meanwhile, the new drug registration process is improved, simplified, and accelerated.

  • George Gu attends DIA meeting in Suzhou 2023

George Gu attends DIA meeting in Suzhou

George Gu, Principal and Head of China at Deallus, recently attended the 2023 DIA China Annual Conference where he participated in an expert panel discussion on "Post-Marketing Medical Activities Based on Specialty Drug Pharmacy Management Platform".

  • Medical Insights to Maximise Product Value

Maximise product value through Medical Insights

Medical Insights is emerging as a transformative organisational capability within Medical Affairs that aims to capture real-world insights through medical channels and use them to maximise product and portfolio value.